Outcome of patients with IgD and IgM multiple myeloma undergoing autologous hematopoietic stem cell transplantation: A retrospective cibmtr study

Donna E. Reece, David H. Vesole, Smriti Shrestha, Mei Jie Zhang, Waleska S. Pérez, Angela Dispenzieri, Gustavo A. Milone, Muneer Abidi, Harold Atkins, Asad Bashey, Christopher N. Bredeson, Willem Bujan Boza, César O. Freytes, Robert Peter Gale, James L. Gajewski, John Gibson, Gregory A. Hale, Shaji Kumar, Robert A. Kyle, Hillard M. LazarusPhilip L. McCarthy, Santiago Pavlovsky, Vivek Roy, Daniel J. Weisdorf, Peter H. Wiernik, Parameswaran N. Hari

Research output: Contribution to journalArticlepeer-review

17 Scopus citations

Abstract

Introduction: Immunoglobulin D (IgD) and IgM multiple myeloma represent uncommon immunoglobulin isotypes, accounting for 2% and 0.5% of cases, respectively. Limited information is available regarding the prognosis of these isotypes, but they have been considered to have a more aggressive course than the more common immunoglobulin G (IgG) and IgA isotypes. In particular, the outcome after autologous hematopoietic stem cell transplantation (auto-HCT) has not been well defined. Patients and Methods: Using the Center for International Blood and Marrow Transplant Research (CIBMTR) database, we identified 36 patients with IgD and 11 patients with IgM myeloma among 3578 myeloma patients who received intensive therapy and auto-HCT over a 10-year period. Results: The progression-free and overall survival probabilities at 3 years were 38% (95% CI, 21%-56%) and 69% (95% CI, 51%-84%) for IgD myeloma, and 47% (95% CI, 17%-78%) and 68% (95% CI, 36%-93%), respectively, for IgM disease. Although formal statistical analysis was limited by the small sample size, these results were comparable to those for IgG and IgA patients autografted during the same time period. Transplantation-related mortality and disease relapse/progression of myeloma were also similar for all isotypes. Conclusion: This analysis demonstrates comparable outcomes in all immunoglobulin isotypes. Therefore, auto-HCT should be offered to eligible patients with IgD and IgM myeloma.

Original languageEnglish (US)
Pages (from-to)458-463
Number of pages6
JournalClinical Lymphoma, Myeloma and Leukemia
Volume10
Issue number6
DOIs
StatePublished - Dec 2010

Bibliographical note

Funding Information:
The CIBMTR is supported by Public Health Service Grant/Cooperative Agreement U24-CA76518 from the National Cancer Institute (NCI), the National Heart, Lung and Blood Institute (NHLBI) and the National Institute of Allergy and Infectious Diseases (NIAID); a Grant/Cooperative Agreement 5U01HL069294 from NHLBI and NCI; a contract HHSH234200637015C with Health Resources and Services Administration (HRSA/DHHS); 2 Grants N00014-06-1-0704 and N00014-08-1-0058 from the Office of Naval Research; and grants from AABB; Aetna; American Society for Blood and Marrow Transplantation; Amgen, Inc.; Anonymous donation to the Medical College of Wisconsin; Astellas Pharma US, Inc.; Baxter International, Inc.; Bayer HealthCare Pharmaceuticals; Be the Match Foundation; Biogen IDEC; BioMarin Pharmaceutical, Inc.; Biovitrum AB; BloodCenter of Wisconsin; Blue Cross and Blue Shield Association; Bone Marrow Foundation; Buchanan Family Foundation; Canadian Blood and Marrow Transplant Group; CaridianBCT; Celgene Corporation; CellGenix, GmbH; Centers for Disease Control and Prevention; Children's Leukemia Research Association; ClinImmune Labs; CTI Clinical Trial and Consulting Services; Cubist Pharmaceuticals; Cylex Inc.; CytoTherm; DOR BioPharma, Inc.; Dynal Biotech, an Invitrogen Company; Eisai, Inc.; Enzon Pharmaceuticals, Inc.; European Group for Blood and Marrow Transplantation; Gamida Cell, Ltd.; GE Healthcare; Genentech, Inc.; Genzyme Corporation; Histogenetics, Inc.; HKS Medical Information Systems; Hospira, Inc.; Infectious Diseases Society of America; Kiadis Pharma; Kirin Brewery Co., Ltd.; The Leukemia & Lymphoma Society; Merck & Company; The Medical College of Wisconsin; MGI Pharma, Inc.; Michigan Community Blood Centers; Millennium Pharmaceuticals, Inc.; Miller Pharmacal Group; Milliman USA, Inc.; Miltenyi Biotec, Inc.; National Marrow Donor Program; Nature Publishing Group; New York Blood Center; Novartis Oncology; Oncology Nursing Society; Osiris Therapeutics, Inc.; Otsuka America Pharmaceutical, Inc.; Pall Life Sciences; Pfizer Inc; Saladax Biomedical, Inc.; Schering Corporation; Society for Healthcare Epidemiology of America; Soligenix, Inc.; StemCyte, Inc.; StemSoft Software, Inc.; Sysmex America, Inc.; THERAKOS, Inc.; Thermogenesis Corporation; Vidacare Corporation; Vion Pharmaceuticals, Inc.; ViraCor Laboratories; ViroPharma, Inc.; and Wellpoint, Inc. The views expressed in this article do not reflect the official policy or position of the National Institute of Health, the Department of the Navy, the Department of Defense, or any other agency of the U.S. Government.

Funding Information:
Angela Dispenzieri has received research funding and honoraria from Celgene Corporation. Muneer Abidi has received research funding from Merck & Co., Inc.; has served as a concultant or been on an advisory/research panel for Millennium Pharmaceuticals, inc.; and has served as a member of a Speaker's Bureau for Genzyme Corporation and Millennium Pharmaceuticals, Inc. Gregory A. Hale has received research/grant funding from that American Cancer Society and the V Foundation for Cancer Research. Shaji Kumar has received research funding/clinical trial support from Celgene Corporation, Cephalon, Inc., Genzyme Corporation, Millennium Pharmaceuticals, Inc., and Novartis Pharmaceuticals Corporation; and has served as a consultant or been on an advisory/research panel for Merck & Co., Inc. Peter H. Wiernik has recieved research funding from and served on a Speaker's Bureau for Celgene Corporation, and has served as a consultant or been on an advisory/research panel for Celgene Corporation, Novartis Pharmaceuticals Corporation, and Pfizer Inc. The remaining authors have no relevant relationships to disclose.

Copyright:
Copyright 2016 Elsevier B.V., All rights reserved.

Keywords

  • Autotransplantations
  • IgA
  • IgG
  • Immunoglobulin isotype

Fingerprint Dive into the research topics of 'Outcome of patients with IgD and IgM multiple myeloma undergoing autologous hematopoietic stem cell transplantation: A retrospective cibmtr study'. Together they form a unique fingerprint.

Cite this